pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

revolo-biotherapeutics PRESS RELEASE ARCHIVE

Jul 18, 2023

Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

Jul 18, 2023

Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

Jun 5, 2023

Revolo Biotherapeutics Presents New Data for ‘1805 in Inflammatory Bowel Disease and Rheumatoid Arthritis at the 5th Treg Directed Therapies Summit

May 22, 2023

Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference

May 10, 2023

Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings

Apr 19, 2023

Revolo Biotherapeutics Announces Positive Topline Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis

Apr 13, 2023

Revolo Biotherapeutics to Present at the 8th Food Allergy Fund Summit

Mar 27, 2023

Revolo Biotherapeutics Announces Completion of Phase 2a Trial of ‘1104 in Allergic Disease

Feb 28, 2023

Revolo Biotherapeutics Presents New Data Demonstrating Long-Lasting Effect of ‘1104 in a Food Allergy Model at the 2023 AAAAI Annual Meeting

Feb 6, 2023

Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy

Jan 5, 2023

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease

Nov 14, 2022

Revolo Biotherapeutics to Present at TIDES Europe 2022

Nov 9, 2022

Revolo Biotherapeutics Announces That the Last Patient in its Phase 2a Trial of ‘1104 in Eosinophilic Esophagitis has Completed the Study

Nov 2, 2022

Revolo Biotherapeutics Awarded Patent for ‘1104 in Acute Treatment of Relapsing Remitting Conditions

Sep 16, 2022

Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

Sep 16, 2022

Revolo Biotherapeutics to Participate in the Sachs Associates 22nd Annual Biotech in Europe Forum for Global Partnering and Investment

Sep 12, 2022

Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis

Sep 8, 2022

Revolo Biotherapeutics to Present at the Baird 2022 Global Healthcare Conference

Jul 14, 2022

Revolo Biotherapeutics Awarded Innovation Passport for ‘1805 in the United Kingdom for the Treatment of Moderate to Severe Rheumatoid Arthritis

May 16, 2022

Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings

May 10, 2022

Revolo Biotherapeutics to Lead Panel Discussion on the Future of Autoimmune Disease Treatment

May 5, 2022

Revolo Biotherapeutics to Participate in the LifeSci Partners Immunology and Inflammation Symposium

Mar 24, 2022

Revolo Biotherapeutics to Participate at SVB Leerink Biopharma Private Company Connect

Feb 25, 2022

Revolo Biotherapeutics To Present New Data at 2022 AAAAI Annual Meeting Demonstrating the Anti-inflammatory Effect of ‘1104 in Acute Respiratory Distress Syndrome

Feb 4, 2022

Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom

Dec 27, 2021

Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors

Oct 28, 2021

Revolo Biotherapeutics Activates Clinical Sites and Opens Enrollment in a Phase 2 Clinical Trial of ‘1104 in Eosinophilic Esophagitis

Oct 26, 2021

Revolo Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference

Oct 21, 2021

Revolo Biotherapeutics Activates Clinical Trial and Commences Enrollment in Phase 2 Clinical Study of ‘1104 in Allergic Disease in the UK

Jul 30, 2021

Revolo Biotherapeutics Announces Clinical Trial Authorization to Initiate Phase 2 Trial of ‘1104 in Allergic Disease in the UK

Jul 15, 2021

Revolo Biotherapeutics to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

Jul 1, 2021

Revolo Biotherapeutics Announces the Appointments of Marla S. Persky and Glen Giovannetti to its Board of Directors

Jun 23, 2021

Revolo Biotherapeutics Announces US FDA Approval of IND Application for Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis

Jun 9, 2021

Revolo Biotherapeutics Enters into Partnership Agreement with Northway Biotech to Manufacture its Novel Binding Immunoglobulin Protein, ‘1805, to Support Phase 2 Trials in Rheumatoid Arthritis and Uveitis

May 14, 2021

Revolo Biotherapeutics to Present at 3rd Annual Treg Directed Therapies Summit

May 4, 2021

Revolo Biotherapeutics Announces Positive Data from Additional Phase 1 Clinical Trial of ‘1104, its Peptide Drug for Allergic Disease

Apr 15, 2021

Revolo Biotherapeutics Enters Manufacturing Agreement with CordenPharma to Scale Up and Manufacture ‘1104 for the Treatment of Eosinophilic Esophagitis and Allergic Disease

Mar 5, 2021

Immune Regulation Announces Rebranding to Revolo Biotherapeutics, Reflecting a Revolutionary Approach to Resetting the Immune System to Treat Autoimmune and Allergic Diseases

Google Analytics Alternative